Clinical use and toxicities of bortezomib in pediatric patients: a systematic review.

ABSTRACT: Proteasome inhibitors (PIs) are FDA-approved to treat adult malignancies. The PI, Bortezomib (BTZ), has been used off-label in pediatric patients but its safety profile in these patients has yet to be systematically assessed. We sought to review the pediatric safety profile of BTZ based on published clinical articles which we compared to publicly available adult safety data from the BTZ drug insert. PubMed and the Cochrane Database were searched up through September 2024. We included published clinical studies that reported adverse events (AEs) which included clinical trials, clinical studies (>10 patients), and clinical series/case reports (≤10 patients). Extracted pediatric safety data was compared to reported adult safety profile from the BTZ drug insert. There was heterogeneity in repo

SUBMITTER: LeBlanc ZC 

PROVIDER: S-EPMC12364856 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature